Journal ArticleDOI
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors
Rafael Molina,Xavier Filella,Josep M. Augé,R. Fuentes,I. Bover,J. Rifa,Victor Moreno,E. Canals,Nuria Viñolas,A. Marquez,Esther Barreiro,Josep M. Borràs,P. Viladiu +12 more
Reads0
Chats0
TLDR
All tumor markers showed a clear relationship with tumor stage and histology and therefore enabled a better histological diagnosis and helped in the diagnosis of non-small cell lung cancer.Abstract:
CEA, CA 125, SCC, CYFRA 21-1 and NSE were prospectively studied in 211 patients with non-small cell lung cancer and compared with clinical parameters (age, sex, Karnofsky Index, symptoms and smoking status), histopathological parameters (stage, histology, tumor size and nodal involvement), biological parameters (LDH and albumin) and the therapy used (surgery, chemotherapy or radiotherapy). Tumor marker sensitivity was CYFRA 21-1: 76%, CA 125: 55%, CEA: 52%, SCC: 33% and NSE: 22%. One of the tumor markers was abnormally high in 87% of the patients with locoregional disease and in 100% of the patients with metastases. Except for NSE, all tumor markers showed a clear relationship with tumor stage and histology and therefore enabled a better histological diagnosis. Abnormal CEA serum levels were mainly found in adenocarcinomas, CA 125 in large-cell lung cancers (LCLC) and adenocarcinomas and SCC in squamous tumors. Eighty-five percent of the patients with SCC levels >2 ng/ml had squamous tumors. Likewise, CA 125 levels <60 U/ml or CEA <10 ng/ml excluded adenocarcinoma or LCLC with a probability of 82 and 91%, respectively.read more
Citations
More filters
Journal ArticleDOI
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin,Christine L. Hann,Edward B. Garon,Moacyr Ribeiro de Oliveira,Philip Bonomi,D. Ross Camidge,Quincy Chu,Giuseppe Giaccone,Divis Khaira,Suresh S. Ramalingam,Malcolm R Ranson,Caroline Dive,Evelyn McKeegan,Brenda Chyla,Barry L. Dowell,Arunava Chakravartty,Cathy E. Nolan,Niki Rudersdorf,Todd A. Busman,Mack Mabry,Andrew Krivoshik,Rod A. Humerickhouse,Geoffrey I. Shapiro,Leena Gandhi +23 more
TL;DR: Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics and Correlative analyses suggest several putative biomarkers of clinical benefit.
Journal ArticleDOI
Breath gas aldehydes as biomarkers of lung cancer.
TL;DR: Sensitivity and specificity of this method were comparable to the diagnostic certitude of conventional serum markers and CT imaging and noninvasive recognition of lung malignancies may be realized if analytical skills, biochemical knowledge and medical expertise are combined into a joint effort.
Journal ArticleDOI
Clinical utility of cytokeratins as tumor markers.
TL;DR: The clinical value of determining soluble cytokeratins protein fragments in body fluids lies in the early detection of recurrence and the fast assessment of the efficacy of therapy response in epithelial cell carcinomas.
Journal ArticleDOI
Label-free photoelectrochemical immunoassay for CEA detection based on CdS sensitized WO3@BiOI heterostructure nanocomposite.
TL;DR: The obtained label-free PEC immunosensor showed an excellent PEC performance toward CEA detection and showed a satisfied result in human serum sample analysis.
Journal ArticleDOI
Six-Color Time-Resolved Förster Resonance Energy Transfer for Ultrasensitive Multiplexed Biosensing
TL;DR: The multiplexed FRET biosensor offers clinically relevant detection limits in the low picomolar concentration range for all five markers, thus providing an effective early screening tool for lung cancer with the possibility of distinguishing small-cell from non-small-cell lung carcinoma.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.
J.P. Bernard,Pierre-Jean Souquet,Jean-Pierre Boissel,Franck Chauvin,R. Cellerino,D. Tumarello,Yvon Cormier,Patricia A. Ganz,Stein Kaasa,J. Pater,E. Quoix,E. Rapp,John D. Williams,B.L. Woods +13 more
TL;DR: A reduction in mortality during the first 6 months with polychemotherapy is shown, although small, and this increase in survival, together with an improved quality of life, suggests that polyChemotherapy should be recommended for patients with non-resectable non small cell lung cancer.
Journal ArticleDOI
An Evaluation of the Carcinoembryonic Antigen (CEA) Test for Monitoring Patients With Resected Colon Cancer
Charles G. Moertel,Thomas R. Fleming,John S. Macdonald,Daniel G. Haller,John A. Laurie,Catherine M. Tangen +5 more
TL;DR: Carcinoembryonic antigen testing was most sensitive for hepatic or retroperitoneal metastasis and relatively insensitive for local, pulmonary, or peritoneal involvement and cancer cures attributable to CEA monitoring are, at best, infrequent.
Journal ArticleDOI
Outcomes of cancer treatment for technology assessment and cancer treatment guidelines
John Fetting,Paul N. Anderson,Harrison Ball,John Benear,Katy Benjamin,Charles L. Bennett,Susan Braun,Harmar Brereton,John Burrows,Charles D. Cobau,Alfred M. Cohen,Leslie C. Ford,Michael Friedman,Patricia A. Ganz,Richard D. Gelber,Holcombe Grier,Gerald Hanks,Robert Justice,Patricia Legant,Mark Levine,Susan K. Parsons,Peter C Raich,Sandra Schafer,Thomas J. Smith,Collier Smyth,A. T. Van Oosterom,James L. Wade,Jane C. Weeks,Rodger J. Winn,Janet Woodcock +29 more
TL;DR: In 1993, the Health Services Research Committee of the American Society of Clinical Oncology (ASCO) charged an Outcomes Working Group with defining the outcomes of adult and pediatric cancer treatment to be used for technology assessment and development of cancer treatment guidelines.